Orexigen Therapeutics, Inc.
(Other OTC/NBB : OREX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.08%132.190.0%$1230.60m
OCGNOcugen, Inc. -2.56%8.740.0%$941.39m
NVAXNovavax, Inc. 10.59%174.8492.9%$613.91m
REGNRegeneron Pharmaceuticals, Inc. 2.71%461.572.7%$556.12m
AMGNAmgen, Inc. 2.62%227.731.3%$540.12m
GILDGilead Sciences, Inc. 2.20%64.621.0%$516.91m
ILMNIllumina, Inc. -0.19%398.853.5%$484.87m
VRTXVertex Pharmaceuticals, Inc. 2.02%211.981.9%$458.30m
ALXNAlexion Pharmaceuticals, Inc. 1.11%150.102.0%$339.49m
BIIBBiogen, Inc. 2.71%270.711.7%$305.38m
CRSPCRISPR Therapeutics AG -0.73%114.650.6%$304.78m
BNGOBioNano Genomics, Inc. 3.62%7.150.0%$275.81m
EXASEXACT Sciences Corp. 0.51%121.6418.4%$251.13m
SGENSeagen Inc. 2.68%149.355.8%$225.25m
PACBPacific Biosciences of California, Inc. 1.70%29.277.2%$176.23m

Company Profile

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company's Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.